Alex Nikitine

Alex Nikitine

Partner
Dr. iur., LL.M., Attorney at Law

Location

Zurich

Contact

Direct phone: +41 58 658 56 32
alex.nikitine@walderwyss.com

Curriculum Vitae

PDF download

Alex Nikitine is head of the Corporate/M&A team at Walder Wyss. His practice focuses on domestic and international M&A transactions, public tender offers, IPOs and other public (ECM/DCM) offerings, private equity and venture capital transactions, corporate governance and general corporate, stock exchange and capital markets laws. His experience for the last 15 years includes numerous transactions in these areas of expertise, in particular with companies in the Life Sciences, Banking or E-Commerce industry.

Alex Nikitine has been recommended by several international directories such as Chambers, IFLR1000 and The Legal 500 as a leading lawyer (by Chambers Global/Europe in both Corporate/M&A and Capital Markets). He is considered "knowledgeable and quick" and "likeable" and is being praised by his "out-of-the-box thinking" and "high level of client orientation" (Chambers, The Legal 500).

Alex Nikitine represents clients in proceedings before the SIX Swiss Exchange, the Swiss Takeover Board (UEK) and the Swiss financial market supervisory authority FINMA. He is a member of the board of examiners for the Swiss certified tax expert exams and a SIX Swiss Exchange recognised representative under art. 58a Listing Rules. He regularly publishes and speaks at conferences in his areas of expertise.

Alex Nikitine studied law at the University of Basel (lic. iur., 2000) and Harvard Law School (LL.M., 2004) and he received a doctorate (PhD; on Swiss and US securities laws) from the University of Zurich (Dr. iur., 2007). In 2009, he worked at Davis Polk & Wardwell LLP in New York, USA.

Alex Nikitine speaks German and English. He is registered with the Zurich Bar Registry and is admitted to practice in Switzerland as well as in the state of New York, USA.

Walder Wyss advised CRISPR Therapeutics (NASDAQ) on USD 280 Million Equity Issuance

ABB acquires Sevensense Robotics

Green Landscaping Group AB (publ) acquires Viva Gartenbau AG

Walder Wyss advised Nasdaq listed Altamira Therapeutics in its sale of majority stake in Altamira Medica

SkyCell AG - USD 57m financing round

Walder Wyss advises WEG S.A. as Swiss counsel in the acquisition of the industrial electric motors and generators business of the Regal Rexnord Corporation

IFLR 1000 Rankings - Walder Wyss as a top-performing law firm ranked

TP24 raises CHF 400m of additional funding from Barclays and M&G

UBS/CS Merger Completed

ITS Kanal Services AG acquires Restclean AG

Walder Wyss advised ANYbotics AG on CHF 45m Series B Round

DSM and Firmenich have completed their EUR 35 bn merger, becoming the leading creation and innovation partner in nutrition, beauty and well-being

ITS Kanal Services Ltd acquires Künzli Group

Swiss medtech company Distalmotion SA closes USD 150m Series F Financing Round

Axiom group acquires Swisslinx

Credit Suisse and UBS to Merge

Cinerius Financial Partners AG acquires a majority stake in Entrepreneur Partners AG

Porsche SE invests in ABB E-mobility’s CHF 325m Pre-IPO Private Placement

PostFinance Ventures, Migros and Serpentine Ventures invest in Properti AG

Bell Food Group invests in Vertical Farming Start-up YASAI

Hotel Saratz Pontresina has new owner

DSM and Firmenich to merge in EUR 42bn transaction, becoming the leading creation and innovation partner in nutrition, beauty and well-being

Zuger Kantonalbank (SIX: ZUGER) is acquiring Immofonds Asset Management AG

Westhive AG raises over CHF 6 million in series A financing round

Astorg acquires CordenPharma from ICIG

Swiss medtech company Distalmotion SA closes USD 90m Series E Financing Round

EH Group raises over CHF 5m Pre-Series A Financing

A.P. Moller Holding acquires Unilabs

Medimaps Group raises CHF 18.55 million

Infoniqa acquires Run My Accounts AG

Revalize aquires SpecPage AG

Scanmarket A/S acquires Symfact AG

Polyphor and EnBiotix sign merger agreement and agreement on sale of Murapavadin

Series B Financing Round of Sulzer & Schmid Laboratories AG

KLAR Partners funds acquire ISS Kanal Services AG

Infoniqa acquires Sage Schweiz AG

Walder Wyss Ltd. acted as counsel to the Lead Managers in the Swiss Steel Group rights offering

Walder Wyss advises CRISPR on USD 600 Million Share Sale Program (ATM)

CHF 7.8 Mio. Series B Financing Round of 1plusX AG

Walder Wyss advises CRISPR on USD 350 Million Share Sale Program (ATM)

Walder Wyss advised ANYbotics AG on CHF 20m Series A Round

Memo Therapeutics raises CHF 14 Mio in Series B Financing Round

Walder Wyss advises CRISPR on USD 520 Million Share Offering

Sunrise acquires Web TV Pioneer Wilmaa

Celanese Corporation (NYSE: CE) Successfully Acquires Nouryon’s Elotex Redispersible Polymer Powders Business

Walder Wyss advised Long State Investment Limited (LSI) on its approx. CHF 31 mio. Investment in WISeKey International Holding Ltd (WISeKey)

Walder Wyss advises CRISPR on USD 310 Million Share Offering

Acquisition of Klinik Gais AG, kardiale Rehabilitation, Psychosomatik und Psychotherapie

Walder Wyss advises Nestlé on CHF 10.2 billion sale of Skin Health Business

Beekeeper raises USD 45 mio.

Walder Wyss advises CRISPR on USD 200 Million Share Sale Program (ATM)

SWISSTO12 raises CHF 18.1mio.

Sobi acquires NovImmune’s Immunology Business in CHF 515 Mio. Deal

Swiss FinTech startup Tradeplus24 closes CHF 120M Series A Financing Round

CHF 15.5 Million financing round in Swiss Startup Oculis SA

Chinese Tech Giant Baidu invests in Swiss Startup aiCTX

Walder Wyss advised 40 North in the acquisition and subsequent sale of shares in Clariant AG

IPO Medartis at SIX Swiss Exchange

Swiss Auris Medical Holding AG (Nasdaq) implements Reverse Share Split through Intra-Group Merger

Tamedia pre-announces takeover of the media promoter Goldbach Group (SIX: GBMN)

Metall Zug (SIX: METN) acquires majority holding in Haag-Streit Holding AG

AMEOS Group acquires Swiss Hospital Seeklinik Brunnen

Walder Wyss advises Evolute Group AG on its CHF 6 mio. A Round

Cembra Money Bank acquires invoice financing provider SWISSBILLING SA

Auris Medical's Public Equity Offering

Zug Estates CHF 100 mio. Bond

Takeover of Pax Anlage AG by Baloîse

Apax / Unilabs

Fairfax Financial to acquire Switzerland's Allied World for USD 4.9bn in cash and stock

Full integration of e-fon AG by UPC Switzerland

Ascom to divest its Network Testing Division to InfoVista

Auris Medical launches ATM Offering

Swiss Life - CHF 600 mio. Hybrid Bonds

Web TV Joint Venture Wilmaa & Teleboy

Bayer and CRISPR Therapeutics form Gene Editing Joint Venture

Management Buy-out Swisscanto/Zürcher Kantonalbank

Cross Border Taking Private Merger of SHL Telemedicine Ltd. (SIX: SHLTN)

Computershare aquires SIX SAG Ltd

EUR 750 mio. Hybrid Bond – Swiss Life

Live Invest Holding AG takes over Skandia Leben AG

Valens Clinics acquire Rheinburg Clinics

Evolva acquires Allylix in Share Exchange Transaction

IPO of Glarner Kantonalbank

L’Oréal purchases Decléor and Carita from Shiseido

Novadaq aquires Aïmago SA

HgCapital acquires 91.85% in P&I Personal & Informatik AG and launches public tender offer

Swiss Life Holding AG issued CHF 500 million Convertible Bonds

IPO Cembra Money Bank

upc cablecom acquires 49%-stake in e-fon AG

Ammann Group sells Implenia stake in Accelerated Bookbuilding Transaction

Sale of Hospital Villa im Park to Genolier Group

Volvo Auto Bank Deutschland transfers Swiss Leasing and Dealer Wholesale Business to FCE Bank

Swiss Life Holding AG issued two Senior Bonds in the amount of CHF 425 million

Swiss Life closed CHF 800 million Loan Exchange Transaction

Swiss Life AG issued a CHF 300 million hybrid bond

Best Price Rule in Public Takeovers – MINOR Changes, MAJOR Effect

Different Requirements for Different Opting Out Clauses under Swiss Public Takeover Rules

Liquidation of unprofitable business by the target company as a permissible condition to a public offer

Liquidation of unprofitable business by the target company as a permissible condition to a public offer

Negotiations in M&A transactions - tips and tricks

Article 725 et seq. CO: (Il-)Liquidity, Capital Loss and Over-Indebtedness – New Duties for Swiss Boards

Commentary on Articles 64, 65 and 68 of the Financial Institutions Act (FinIA)

“Officer’s Certificates” in M&A transactions

Revised SIX rules on ad hoc publicity effective as of 1 July 2021

IPO Readiness - Stolpersteine auf dem Weg zum Börsengang

Covid-19 Update: Emergency Loan Scheme for Start-ups

Guidelines on Shareholders’ Meetings under COVID-19 Ordinance 2

Adjusted Disclosure Rules Under Swiss Corporate Law («GAFI-Rules»); Criminal Sanctions Will Apply

Der Erfolg unserer «Startuppers» ist die grösste Motivation

Initial Public Offering (IPO) 2017 / Switzerland

IPO Guide Switzerland (SIX Swiss Exchange) / Listing Requirements by the SIX Swiss Exchange

Commentary on the Financial Market Infrastructure Act (FMIA)

Management Buy-out - Pre-Contractual Disclosure Obligations of the Managers

Wealth Tax on Shares in Start-ups – New Rules in the Canton of Zurich

Mergers & Acquisitions Practice Area Review

Changes to Swiss Rules on Disclosure of qualified Shareholdings

Commentary on articles 8-11, 30 VegüV

Venture capital investment in Switzerland: market and regulatory overview

Mergers & Acquisitions Practice Area Review

Adjustments to the Swiss Corporate Governance Framework

Cross-Border Equity Capital Markets – Switzerland

Debate about new rules under the "Minder-Initiative"

The independent shareholders" representative (unabhängiger Stimmrechtsvertreter) under the ordinance against excessive compensations at publicly listed corporations («VegüV»): Overview – Select Issues – Approach

Implementation of the «Minder-Initiative» – The implementing ordinance («VegüV») has been presented.

Breach of the disclosure obligation (art. 20 SESTA) and of the banking law related «fit-and-proper»-requirement (Gewährspflicht)/Comments on Supreme Court decision BVGE 2012/33

Draft Ordinance on Minder Initiative: No groundbreaking rules; interesting clarifications.

Venture capital investment in Switzerland: market and regulatory overview

Revision of Swiss Stock Exchange Law and Corporate Governance Rules

Minder initiative approved – New Corporate Governance Rules for Swiss Public Companies

Cross-Border Equity Capital Markets – Switzerland

SIX Swiss Exchange: Yes to Attorney Work Product Privilege in Investigations by the SIX and Yes to Substantial Fines for Breaches of the SIX Listing Rules

Use of Share Purchase Agreements in European Jurisdictions: Switzerland

Merger – Mandatory Tender Offer – Opting-out

USA – Statutory Regulation of Management Compensation

Golden Handshakes, Golden Parachutes and similar arrangements in M&A transactions

The liability of the Board of Directors and Managers under Article 754 para. 1 CO for business judgements: Concept and structure of the business judgement rule in the Corporate Governance context

Recognitions


Other lawyers